Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

US7250407B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Jean-Louis Dasseux · Mannheim, DE
• Renate Sekul · Ladenburg, DE
• Klaus Büttner · Epfenbach, DE
• Isabelle Cornut · Edingen-Neckarhausen, DE
• Günther Metz · Edingen-Neckarhausen, DE
• Jean Dufourcq · Pessac, FR

Key dates

• Filing date: Nov 16, 2004
• Grant date: Jul 31, 2007
• Expiry date: Jul 12, 2025

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K48/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, preproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native ApoA-I; and modified native ApoA-I having one or more amphipathic helices replaced by the nucleotide sequences of one or more ApoA-I agonists; for the treatment of disorders associated with dyslipoproteinemia, including cardiovascular disease, atherosclerosis, restenosis, hyperlipidemia, and other disorders such as septic shock.